OR-CIRIUM
3.6.2021 13:02:11 CEST | Business Wire | Press release
Americans are confident to fly again, with 78% of travelers intending to travel for leisure, according to results from a new survey from Cirium , the aviation analytics company. Of those who travel for business, 67% indicate their employer will permit travel in the next three to six months. Some 40% of respondents who intend to return to the skies plan to fly this summer. However, only a small minority had plans to travel by air for major holidays such as the July 4th weekend (16%) and Labor Day weekend (17%).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210603005493/en/
The firm interviewed 2,140 adults across the US between May 11 and 17, 2021, in a nationally representative sample. The margin of error in the reported data did not exceed +/- 3% at the 95% confidence level.
A strong majority of US travelers (90%) intend to fly at some point in the future, and 64% are planning to fly within the next 12 months.
More than three-quarters (78%) of those with plans to travel this year are only planning for domestic trips. Only 22% expect to fly internationally in 2021. The survey also reveals that over one-quarter of respondents reported having taken a flight since the pandemic. Some 60% of respondents indicated that the pandemic will have no impact on their long-term travel plans.
“Cirium’s traveler survey identifies the confidence of the US in flying again, with a majority taking to the skies domestically already—mainly to visit family. The results indicate that the challenges facing US airlines is not lack of travel demand, but on the health and safety measures in place at the airport and in flight,” said Jeremy Bowen, CEO at Cirium.
“US business travel may see some green shoots of recovery in the fall of 2021, as corporations plan to release restrictions on travel.”
While US airlines are increasing domestic flights for summer 2021 and Americans show interest in flying again, travelers expressed health and safety concerns, which impact their travel decisions.
Respondents strongly support the adoption of health passports for future air travel, with 59% supporting a requirement to carry mandatory passes to fly—though 20% disagree with the idea. When asked what airline measures would increase their motivation to fly, the majority of participants identified mandatory mask-wearing (61%) and improved cleaning processes (61%) as the top two measures.
The majority of respondents (78%) identify leisure travel as the main purpose for travel, however the survey reveals optimism for business travel returning in the fall.
Of the respondents who said they travel for business, just 34% were currently permitted to travel by their employer, increasing to 67% within the next three to six months.
The rise in working from home seems to have had little effect on the likelihood to travel for business reasons, as half of US respondents claim there is no change and nearly a quarter (24%) said they are more likely to travel for business.
More than half the respondents reported that they could work remotely and 40% of these respondents claim that the pandemic has increased the chances that they would combine a vacation with work.
Additional insights on air travel in the full report:
- Awareness of new startup airlines in the US
- Long-haul flying on single-aisle aircraft
- Lounge usage and time spent at the airport
- The influence of sustainability concerns on travel
Click here to see the full US Cirium Traveler Intelligence Report.
Complete data with results by age group, US region and gender available on request. Similar data for the UK is available. The survey into traveler sentiment was carried out by independent market intelligence firm AudienceNet on behalf of Cirium.
Ends
For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter .
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX , a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005493/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
